KALA BIO Inc. (KALA)
NASDAQ: KALA
· Real-Time Price · USD
1.54
0.00 (0.00%)
At close: Oct 03, 2025, 3:59 PM
1.54
0.00%
After-hours: Oct 03, 2025, 07:51 PM EDT
Company Description
Kala Bio, Inc. is a biopharmaceutical company.
It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases.
The company was founded by Justin Hanes, Robert S.
Langer and Colin R.
Gardner in 2009 and is headquartered in Arlington, MA.
KALA BIO Inc.
| Country | United States |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Todd Bazemore |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts United States | |
| Website | https://www.kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd Bazemore | Interim Chief Executive Officer, President & Chief Operating Officer |
| Mary Reumuth CPA | Chief Financial Officer, Treasurer & Secretary |
| Carl Rennie | Executive Director of Account Management |
| Darius Kharabi J.D., M.B.A. | Chief Business Officer |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Dr. Justin Hanes Ph.D. | Founder & Chair of the Scientific Advisory Board |
| Dr. R. Kim Brazzell Ph.D. | Head of R&D and Chief Medical Officer |
| Jill S. Steier | Executive Director of Investor Relations & Corporate Communications |
| Josiah Craver | Senior Vice President & Corporate Controller |
| Vincent Kosewski | Senior Vice President of Manufacturing & Supply Chain Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Oct 02, 2025 | 4 | Filing |
| Oct 02, 2025 | 8-K/A | [Amend] Current Report |
| Oct 01, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Oct 01, 2025 | 8-K | Current Report |
| Sep 29, 2025 | 8-K | Current Report |
| Sep 18, 2025 | 8-K | Current Report |
| Sep 11, 2025 | SCHEDULE 13G | Filing |
| Sep 11, 2025 | SCHEDULE 13G | Filing |
| Sep 02, 2025 | 4 | Filing |